US 7527791
Forward Citations
How Engineered Antibodies Target TGF-beta Proteins to Fight Cancer
Patents that cite US 7527791 — inventions that reference this patent as foundational prior art in their own applications. High forward citation counts indicate an influential patent.
CITED BY
756 patents
IN PATENTLENS
0
Citation network
This patent has been cited by 756 later patents. Citation detail pages are being built out in Phase 2.
Forward citation data is sourced from the USPTO patent database. Only patents indexed in PatentBrief are shown as links.